SCHEMBL29636285

SCHEMBL29636285

COc1ccc(-n2cnc3c(Br)cccc32)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.61
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PI4KA P42356 1/20 0.49
PI4K2B Q8TCG2 1/20 0.49
PI4K2A Q9BTU6 1/20 0.49
PI4KB Q9UBF8 1/20 0.49
FGFR1 P11362 3/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
MAPK10 P53779 1/20 0.48
NCOA1 Q15788 1/20 0.48
NCOA3 Q9Y6Q9 1/20 0.48
KDR P35968 1/20 0.47
SRC P12931 1/20 0.46
GSK3B P49841 1/20 0.44
XDH P47989 1/20 0.44
GRM1 Q13255 5/20 0.44
KCNH2 Q12809 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781129 1.00 HTT (0.61) HTTALDH1A1MAPTSMN1; SMN2PI4KA
SCHEMBL28794601 0.85 HTT (0.54) HTTALDH1A1MAPTSMN1; SMN2PI4KA
SCHEMBL29745019 0.85 HTT (0.54) HTTALDH1A1MAPTSMN1; SMN2PI4KA
SCHEMBL21436090 0.83 HTT (0.44) HTTALDH1A1MAPTSMN1; SMN2PI4KA
SCHEMBL7605205 0.82 EGLN1 (0.46) HTTFGFR1SRC
SCHEMBL900261 0.80 GRM2 (0.46) HTTFGFR1SRCGRM1HCAR1
SCHEMBL31498297 0.77 HTT (0.56) HTTALDH1A1MAPTSMN1; SMN2PI4KA
SCHEMBL29907282 0.77 L3MBTL1 (0.55) HTTALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL27150328 0.77 L3MBTL1 (0.55) HTTALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL10695254 0.76 HTT (1.00) HTTALDH1A1MAPTSMN1; SMN2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-09-08 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION C9, C1S, ZC3HAV1 HTT 1349/4885ALDH1A1 1131/4885MAPT 4605/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S HTT 1337/4885ALDH1A1 1146/4885MAPT 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.